Zucara Therapeutics Company
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.
Industry:
Geroscience
Headquarters:
Vancouver, British Columbia, Canada
Zip:
1-10
Founded Date:
2015-01-01
Employees Number:
1-10
Acquisitions Number:
9
Investors Number:
26807893
Total Funding:
26807893
Last Funding Date:
Grant
Last Funding Type:
Grant
Register and Claim Ownership